Myeloma care links disease control with organ protection
Multiple myeloma is a plasma-cell cancer that may cause bone lesions, anaemia, kidney injury, high calcium or other organ effects. Related conditions such as MGUS and smouldering myeloma do not always require immediate treatment.
Treatment selection depends on symptoms, risk features, transplant fitness, frailty, kidney function and previous exposure. Bone protection, infection prevention, thrombosis planning, pain care and renal support are part of the pathway.
The team should identify the myeloma-defining event or organ risk, not rely on an isolated protein result.
Who may be considered?
Specialist review may help when the source diagnosis and treatment timeline raise a practical question about myeloma diagnosis, risk and treatment sequence.
- A new plasma-cell disorder needing distinction between precursor and active disease.
- Active myeloma requiring induction and transplant-fitness review.
- High-risk cytogenetic disease needing closer strategy review.
- Relapse after one or more treatment classes.
- Bone, kidney, infection or neuropathy complications affecting treatment choice.
What the specialist team must confirm
Specialists review marrow pathology and flow, serum and urine protein studies, free light chains, calcium, blood counts, kidney function, whole-body imaging, cytogenetics, symptoms, frailty and prior therapies.
Key points for this treatment
From myeloma-defining event to long-term disease control
Treatment and supportive care are sequenced around risk, transplant eligibility, response and cumulative toxicity.
Transplant, maintenance and relapse planning
Eligible patients may discuss autologous transplant after induction, while others use non-transplant regimens adapted to fitness. Maintenance aims to extend control but adds ongoing burden and toxicity.
At relapse, the team reviews refractory drug classes, duration of prior response, organ function and available antibody, cellular, targeted or trial options.
Limits, burdens and realistic expectations
Myeloma is often controllable but remains prone to relapse. Treatment can cause infection, thrombosis, neuropathy, low blood counts and organ toxicity. Response depth does not guarantee duration, and frailty can make an intensive plan harmful.
New weakness, loss of bladder or bowel control, severe bone pain, confusion, dehydration, reduced urine, fever or sudden breathlessness requires urgent local care.